FDA rejects United's potential PAH drug due to a manufacturing issue

Josh Sullivan

United Therapeutics said Monday that it received a complete response letter for its potential pulmonary arterial hypertension drug Tyvaso DPI, due to an issue with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA rejects United's potential PAH drug due to a manufacturing issue

Josh Sullivan

Sign up to read this article for free.

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Flagship biotech Valo Health ends 2024 with mid-stage fail

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

FDA re­jects Unit­ed's po­ten­tial PAH drug due to a man­u­fac­tur­ing is­sue

Josh Sullivan

Sign up to read this article for free.

more like this

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

No­var­tis ends Phase 1 ra­dio­phar­ma tri­al; Solve Ther­a­peu­tics pur­sues $75M round

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

FDA rejects United's potential PAH drug due to a manufacturing issue

Neumora's major depression drug flunks first of three Phase 3 trials

Roche circles back to China biotech with $80M deal for lung cancer ADC

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Flagship biotech Valo Health ends 2024 with mid-stage fail

Novartis ends Phase 1 radiopharma trial; Solve Therapeutics pursues $75M round

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval